Genmab, GlaxoSmithKline deal

Genmab agreed to transfer its deal with GlaxoSmithKline to co-develop and commercialize Arzerra ofatumumab for cancer indications to Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland). Genmab will...